FOCUS-"Last hope": Eager Germans are 用意が出来ている to 支払う／賃金 for 負わせる-loss 麻薬
Interviews with doctors 示す strong Wegovy 需要・要求する
*
患者s 表明する 利益／興味 にもかかわらず 欠如（する） of 保険 ニュース報道
*
開始する，打ち上げる in third European market planned for end-July
*
Novo says cannot 支配する out 供給（する） 延期するs and 不足s
By Ludwig Burger and Maggie Fick
FRANKFURT/LONDON, July 25 (Reuters) - 失望させるd after countless failed diet and 演習 試みる／企てるs, 41 year-old Jessica Lenth from Hamburg has started putting money aside for a 麻薬 that she sees as a possible door to a life without obesity.
Interviews with seven doctors and two other 可能性のある 使用者s of Wegovy from Germany, where Novo Nordisk's 負わせる-loss 麻薬 will become 利用できる at the end of July, show the office 行政官／管理者 isn't alone.
"It's a bit like a last hope I 粘着する to. I've just learnt the price. For now, I'll be saving a bit of money before I try to get it," Lenth told Reuters by telephone.
The doctors say they are 審理，公聴会 a 類似の message from hundreds of obese or overweight 患者s and 推定する／予想する high 需要・要求する for Wegovy prescriptions even though public health 保険 計画（する）s covering about 90% of Germans will not foot the 法案.
The interviews 示唆する many 患者s will be 用意が出来ている to 支払う／賃金 themselves for the 週刊誌 注射, at an 初期の cost of about 170 euros ($190) a month but just over 300 euros longer 称する，呼ぶ／期間／用語.
For the 10% of Germans with 私的な health 保険, ニュース報道 will depend on 契約 条件. Allianz says it will 支払う／賃金 if a 内科医 診断するs a 医療の need while Debeka said its 計画（する）s 除外する 負わせる-loss 治療s.< /p>
患者 支持するs and 内科医s welcomed the arrival of Wegovy in Germany, where 18.5% of adults are obese, more than the European Union 普通の／平均（する） of 16%. The Robert Koch 学校／設ける for public health says 病気s linked to 超過 団体／死体 負わせる 提起する／ポーズをとる a かなりの 重荷（を負わせる） on health and social 安全 systems.
Wegovy's 開始する，打ち上げる in Germany, its third European market and the 地域's largest, comes as Novo is ramping up 生産／産物 to 会合，会う 急に上がるing 需要・要求する in the 部隊d 明言する／公表するs, where the 麻薬 sells for as much as $1,350 a month.
The Danish drugmaker told Reuters it would closely 監視する prescriptions in Germany to 確実にする that people with obesity can start and continue 治療.
"にもかかわらず, if 需要・要求する is higher than 推定する／予想するd, we cannot 支配する out the 可能性 of 供給（する） 延期するs and 不足s in the coming months," it said.
Novo's 株 have 決起大会／結集させるd nearly 120% since Wegovy debuted in June 2021, making it Europe's second-most-価値のある 名簿（に載せる）／表（にあげる）d company after LVMH.
In Germany, Wegovy will be 治めるd with the same 注射 pen used in Norway and Denmark, not the one used in the 部隊d 明言する／公表するs to 避ける hitting 供給（する）s there.
A swift uptake could にもかかわらず その上の 緊張する Novo's ability to 会合，会う 需要・要求する.
Wegovy's introduction in Germany is likely to 動かす the 審議 over what 構成するs a 医療の need in a nation that doctors said often sees obesity as a "lifestyle choice" rather than a chronic 病気.
Dr. Sylvia Weiner, who runs an obesity clinic at Sana Klinikum Offenbach 近づく Frankfurt, has fielded questions about Wegovy from several dozen 患者s in the past few months and 心配するs many more.
"We are really waiting for Wegovy," she said. "患者s are so desperate in Germany that t hey will 支払う／賃金 out of their pocket for the 医薬."
POTENTIAL IMPACT
Used と一緒に diet and 演習 changes, Wegovy has been shown to help obese people lose about 15% of their bodyweight.
But 臨床の 裁判，公判 data shows people 回復する 負わせる after they stop taking it. Reuters 報告（する）／憶測d last week that most U.S. 患者s stopped using 負わせる-loss 麻薬s within a year.
Dr. Karl Rheinwalt, an obesity specialist at St Franziskus-Hospital Cologne, reckons the cost will 限界 uptake in Germany.
But Munich-based Dr. Thomas Horbach - who like Weiner and Rheinwalt 成し遂げるs gastric bypass and other bariatric 外科s - says some of his 患者s who are overweight but not diabetic already 支払う／賃金 for Ozempic, a 糖尿病 麻薬 also made by Novo, themselves.
Using the same active 成分 at a lower dose, Ozempic costs いっそう少なく per milligram of active 実体 than Wegovy.
"My experience is that people will be able to 支払う／賃金 for it out of (their own) pocket," said Horbach. He said the 禁止（する） on reimbursement by public health 計画／陰謀s under a 1980s 法律 that categorises 負わせる-loss therapies as lifestyle 麻薬s, 差別するs against people with low incomes.
Novo said prescription 麻薬s in Germany were 一般に 除外するd from rebate or coupon 昇進／宣伝s.
Some specialists say the lifestyle 麻薬 分類 増強するs a 広範囲にわたって held 見解（をとる） that those with obesity and 関係のある 条件s such as 糖尿病 or high 血 圧力 have themselves to 非難する.
"患者s 苦しむ enormously from the stigma because they feel 孤立するd, because it's a 明白な 病気 that has been 不公平に associated with せいにするs such as laziness," said Dr. Juergen Ordemann, another 外科医 and 長，率いる of obesity at Berlin's Vivantes hospital chain.
Without public health 保険 for obesity 麻薬s, and very 限られた／立憲的な 支払い（額）s for obesity-明確な／細部 psychotherapy, 治療 in Germany often means 外科 for the most 厳しい 事例／患者s, with a BMI of around 50.
DIET AND EXERCISE
All the doctors interviewed by Reuters said they ーするつもりである to 定める／命ずる Wegovy と一緒に structured diet and 演習 programmes.
Many worried that 供給（する）s would be その上の 緊張するd by 非，不，無-obese people 捜し出すing "vanity" prescriptions - a 関心 反映するd in a Novo 声明 last week 説 内科医s should "定める／命ずる responsibly".
Doctors say they will まず第一に／本来 consider Wegovy for 患者s who are at the 早期に 行う／開催する／段階s of obesity, with a BMI of around 30 or わずかに higher, and not recommended for 外科.
厳しく 影響する／感情d 患者s would still 要求する 外科 but they could use the 麻薬 to 準備する for their 手続きs and help them 持続する a lower 負わせる afterwards.
Michael Wirtz, a civil 工学 事業／計画（する） 経営者／支配人 from Winsen an der Luhe in Lower Saxony, had gastric bypass 外科 in 2011 that helped him lose 70 kg.
He has since 回復するd 25 kg, however, and is considering Wegovy と一緒に lifestyle changes.
"Without it, I would probably have to think about changing my 職業 to 緩和する the 強調する／ストレス level, but that would of course mean a lower income," said Wirtz, 追加するing that he might 取り消す some subscriptions to help afford the cost.
Irina Ernstberger, a 66 year-old retiree, said she considers Wegovy a fallback 選択 after she lost 負わせる to 井戸／弁護士席 below the obesity threshold with the help of Ozempic.
Speaking to Reuters at her house in Munich, Ernstberger said she is on the 権利 跡をつける, having 持続するd her 負わせる for thr ee months even after getting off Ozempic, which she paid for herself.
The 投資 was 価値（がある） it.
"Sure, it costs a lot, not just the 薬／医学 itself, but also a 完全に new wardrobe. But buying new 着せる／賦与するs was fun," she said.
($1 = 0.8984 euros)
(報告（する）／憶測ing by Ludwig Burger in Frankfurt and Maggie Fick in London, Patricia Weiss in Frankfurt; Editing by Josephine Mason and Catherine Evans in London)
